Brad Wilson

Angel

Portfolio

companies

Oxford Cancer Analytics

Oxford Cancer Analytics develops blood tests for early cancer detection using proteomics and artificial intelligence.

Brad Wilson

former European President of GlaxoSmithKline

Seed6 September 2021

£1.3M

Oxford Cancer Analytics raises £1.3m in seed funding to expand its early lung cancer detection platform

The oversubscribed round drew participation from Cancer Research UK, Civilisation Ventures, and various angel investors.

"to shape a future in which early cancer detection becomes the norm rather than the exception"

— Peter Liu, CEO